Product Description
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: COVID-19
Phase 3: Hepatitis C, Chronic
Phase 2: Hepatitis C, Chronic|Hepatitis A|Hepatitis C
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| C-DIAMOND | N/A |
Unknown status |
Hepatitis C, Chronic|Hepatitis A |
2021-07-31 |
|
| ChiCTR2000031734 | N/A |
Recruiting |
Pneumonia|COVID-19 |
2020-05-29 |
|
| ChiCTR2000030259 | N/A |
Recruiting |
Pneumonia|COVID-19 |
2020-04-30 |
|
| ASC-CTP-HS-01 | P4 |
Completed |
COVID-19 |
2020-04-15 |